INTRODUCTION
Epidemiologic and preclinical studies have associated several biobehavioral signaling pathways with cancer progression. [1] [2] [3] [4] [5] Recent studies have focused on the neuroendocrine regulation of breast tumor progression, mediated through activation of the sympathetic nervous system and release of the adrenergic neurotransmitters epinephrine and norepinephrine. These studies have shown that adrenergic signaling can regulate several pathways necessary for breast tumor progression and metastasis through direct effects on tumor cells and the tumor microenvironment. [1] [2] [3] [4] [5] Preclinical models have demonstrated that epinephrine and norepinephrine induce tumor cell invasion and migration, key steps in tumor progression and the pathogenesis of metastasis. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Norepinephrine exerts chemokinetic and chemotactic effects on breast tumors, increasing the number of and influencing the direction of migrating cells. 8, 9 Similar findings have been reported for several other tumor types including ovarian, colon, and prostate tumors. [9] [10] [11] 14, 15 ␤-adrenergic signaling is also involved in the regulation of immune responses to breast tumor cells, 16 the inhibition of apoptosis, 17, 18 and the induction of vascular endothelial growth factor expression. [13] [14] [15] 19 In vivo studies of ␤-adrenergic signaling in breast tumor models have demonstrated an association with increased nodal involvement and development of metastasis but no effect on primary tumor growth. 16 It has been shown that these effects are mediated through the ␤-adrenergic pathway, specifically the ␤ 2 receptor, and are inhibited by ␤ 2 receptor antagonists (eg, propranolol). [8] [9] [10] [11] [12] 15, 16, 20 Similar inhibitory effects are not observed with the use of ␤ 1 selective antagonists (eg, atenolol). [8] [9] [10] 15 On the basis of this extensive preclinical evidence, we hypothesized that the use of a beta blocker with ␤ 2 receptor activity before breast cancer diagnosis would result in a lower risk of local tumor invasion, nodal involvement, or metastatic disease and, in addition, continued use of these medications post diagnosis would result in a decrease in breast cancer-specific mortality. A series of matched population-based observational studies were performed to determine associations between the use of propranolol, a nonselective ␤ 1 /␤ 2 antagonist (␤ 1 :␤ 2 receptor activity, 1:2), 21 or atenolol, a selective ␤ 1 antagonist (␤ 1 :␤ 2 receptor activity, 35:1), 21 and the risk of local tumor invasion at diagnosis, nodal and metastatic involvement at diagnosis, and breast cancer-specific mortality.
PATIENTS AND METHODS

Data Sources
This study was conducted by using prescription dispensing data from Ireland's General Medical Services (GMS) scheme, linked to patient records from the National Cancer Registry Ireland (NCRI) between January 1, 2000, and December 31, 2007. The GMS provides taxpayer-funded health care, including medicines, to approximately one third of the Irish population (1.35 million people). 22 Eligibility for the scheme is primarily by means test and age, with patients older than age 70 years automatically qualifying for entry before January 2009. 23 All medicines dispensed and basic demographic information are recorded for each patient. The NCRI database is a population-based tumor registry that collects detailed patient characteristics, comprehensive tumor details, treatment data, and mortality data for each newly diagnosed cancer patient. These data are actively collected by NCRI tumor registration officers from pathology reports and patient records. Mortality data, including cause and date of death, are obtained from death certificates. Tumor registration is estimated to be in excess of 98% complete. 24 Both data sets are well characterized and have been used extensively for health care research.
25-27 Data usage agreements have been established with the GMS and NCRI, and all potentially traceable patient identifiers were removed from the data before analysis.
Source Population and Exposure Definitions
The source population consisted of all women age 40 years or older with a diagnosis of stage I to IV 28 invasive breast cancer between January 1, 2001, and December 31, 2006. Patients were excluded if they had a diagnosis of invasive breast cancer before January 1, 2001, or if their initial diagnosis of breast cancer was at death. All patients were required to have GMS eligibility in the year before breast cancer diagnosis. Systematic breast cancer screening in the source population was commenced in Ireland on a limited basis in February 2000. The service was extended to cover all women between the ages of 50 and 64 years by the year 2009. 29 Treatment exposure was defined as follows: propranolol users were identified as all patients filling a prescription for propranolol in the year before breast cancer diagnosis and no prescription for another beta blocker during that time; atenolol users were identified as all patients filling a prescription for atenolol in the year before breast cancer diagnosis and no prescription for another beta blocker during that time; nonusers were identified as all patients without a prescription for any beta blocker in the year before breast cancer diagnosis.
Study Covariates and Outcomes
Prescription refill data from the GMS database were used to identify relevant medication use from 1 year before breast cancer diagnosis. The duration of beta blocker exposure was calculated by using the number of days' supply on each dispensed prescription. The number of distinct medication classes dispensed in the year before breast cancer diagnosis was used as a validated measure of comorbidity. 30 Medications with the same initial five characters of World Health Organization Anatomic Therapeutic Chemical (WHO-ATC) 31 classification were considered the same class for this purpose. This comorbidity score is comparable with the Charlson comorbidity score for predicting 1-year all-cause mortality (c ϭ 0.745), and it also reasonably predicts the number of physician visits. 30 The NCRI database was used to identify demographic covariates, socioeconomic deprivation scores, 32 smoking status, tumor characteristics, treatment data (chemotherapy: yes/no), and mortality. Study outcomes were defined as T4(a-d) breast tumor at diagnosis, 28 N2 or N3 or M1 breast tumor at diagnosis, 28 grade 1 or 2 breast tumor at diagnosis, and time from breast cancer diagnosis to breast cancer-specific mortality (breast cancer as recorded cause of death on death certificate).
Matching
Propranolol and atenolol users were separately matched to two randomly selected nonusers from the same control population by using a greedy matching algorithm. 33 Matching variables were selected for each analysis outcome by using a combination of a priori and empiric considerations. Propensity scores for matching were separately estimated for propranolol exposure and atenolol exposure. Variables associated in previous studies with a delay in breast cancer presentation or participation in cancer screening and other healthy behaviors were included in the propensity score models.
34-36 These included socioeconomic deprivation scores, marital status, smoking history, and the use of long-term prophylactic medications (eg, statins or aspirin). For the analyses of T4 tumor and tumor grade at diagnosis, users were matched to nonusers by age (Ϯ 5 years), comorbidity score (Ϯ 10 prescriptions), and propensity score (Ϯ 0.000025). For the analysis of N2/N3/M1 tumor at diagnosis, users were matched to nonusers by age (Ϯ 5 years), comorbidity score j Three women in the nonuser group received propranolol during follow-up. The mean duration of propranolol use for these women was 45 days. (Ϯ 10 prescriptions), propensity score (Ϯ 0.00015). and tumor size (Ϯ 0). For the analysis of time to breast cancer-specific mortality, women taking propranolol or atenolol at the time of breast cancer diagnosis were matched to nonusers by age (Ϯ 5 years), comorbidity score (Ϯ 10 prescriptions), tumor grade (Ϯ 0), and tumor stage (Ϯ 0).
Statistical Analysis
Propensity scores for matching were estimated by using logistic regression (SAS, PROC LOGISTIC; SAS Institute, Cary, NC), with the outcome being exposure to the respective beta blocker. Conditional logistic regression (SAS, PROC LOGISTIC) was used to estimate odds ratios (ORs) and 95% CIs for a T4 tumor at diagnosis, an N2/N3/M1 tumor at diagnosis, and a grade 1 to 2 tumor at diagnosis. The cumulative probability of breast cancer-specific' mortality was estimated from Kaplan-Meier plots (SAS, PROC LIFETEST). Multivariable Cox proportional hazards models adjusted for age, stage, grade, and comorbidity were used to estimate hazard ratios (HRs) with 95% CIs for breast cancer-specific mortality (SAS, PROC PHREG). Survival analyses were conducted on an as-matched basis. Observations were censored at the time of breast cancer-specific mortality, non-breast cancer-specific mortality, or end of follow-up (December 31, 2007, or 5 years). All patients were followed for between 1 and 5 years from breast cancer diagnosis. Statistical analyses were performed with SAS version 9.2 (TS2M0 x64 VSPRO).
RESULTS
A source population of 5,801 women was identified from the linked GMS/NCRI database (Fig 1) . This GMS-eligible source population differed as expected from the full NCRI population, with a higher mean age (67.4 v 61.6 years) and a greater proportion of women with the highest level of socioeconomic deprivation (34.7% v 27.6%). Three exposure groups were identified from this source population. Propranolol users consisted of 70 women taking propranolol and no other beta blocker in the year before breast cancer diagnosis. Atenolol users consisted of 525 women taking atenolol and no other beta blocker in the year before breast cancer diagnosis. Nonusers consisted of 4,738 women not taking a beta blocker in the year before breast cancer diagnosis. Table 1 and Table 2 outline the characteristics of the matched propranolol and atenolol groups with respect to selected variables.
The median duration of propranolol exposure in the year before diagnosis was 232 days. The median daily dose of propranolol during this time was 80 mg. Propranolol users were significantly less likely to present with a T4 tumor at diagnosis compared with nonusers matched by age, comorbidity, and propensity score (Table 3 ; OR, 0.24; 95% CI, 0.07 to 0.85). During the same period, no significant difference in the incidence of T4 tumors between atenolol users and nonusers was observed (Table 3 ; OR, 1.31; 95% CI, 0.91 to 1.88). Propranolol users were also significantly less likely to present with N2/N3 nodal involvement or metastatic disease compared with nonusers matched by age, comorbidity, propensity score, and tumor (Table 3 ; OR, 0.20; 95% CI, 0.04 to 0.88). No effect was observed for women taking atenolol (Table 3 ; OR, 1.10; 95% CI, 0.72 to 1.70). Stratifying T4 and N2/N3/M1 tumor rates by propranolol exposure showed that there were no T4 tumors (0 of 33 v 3 of 32) and one N2/N3/M1 tumor (1 of 27 v 1 of 27) in women taking propranolol for longer than the median duration of use. Propranolol users were significantly more likely to present with grade 1 or 2 tumors at diagnosis (Table 3 ; OR, 2.33; 95% CI, 1.19 to 4.56). There was, however, a higher proportion of missing tumor grade data for nonusers in this analysis. Stratification of grade by tumor stage provides a likely explanation for this, because the proportion of missing grade data increased with tumor stage, and nonuse of propranolol was associated with higher tumor stage (Tables 1 and 3 ; T4 analysis). Sensitivity analyses were undertaken to determine the effect of including tumor grade as a matching variable in the T4 and N2/N3/M1 analyses. These did not have a notable effect on the observed associations. There were four (8.9%) breast cancer-specific deaths among propranolol users for an incidence rate of 26.5 per 1,000 woman years and 20 (22.2%) deaths among nonusers matched by age, tumor grade, tumor stage, and comorbidity for an incidence rate of 67.9 per 1,000 woman years (Table 4 ). The median follow-up was 3.5 years for propranolol users and 3.6 years for matched nonusers. The median duration of propranolol exposure post breast cancer diagnosis was 1.92 years. The median daily dose of propranolol during this time was 60 mg. At 5 years post breast cancer diagnosis, the risk of breast cancer-specific mortality was 81% lower for propranolol users than for nonusers (Fig 2A; Table 4 ; HR, 0.19; 95% CI, 0.06 to 0.60). Rates of non-breast cancer-specific mortality were similar between propranolol users and nonusers. There was no difference in the cumulative probability of breast cancer-specific mortality between atenolol users and matched nonusers, 26.8% v 26.0% ( Fig  2B; Table 4 ; HR, 1.08; 95% CI, 0.84 to 1.40). These analyses were repeated, excluding patients with stage IV breast tumors. Propranolol users continued to have a significantly lower risk of breast cancer-specific mortality, compared with matched nonusers (HR, 0.20; 95% CI, 0.04 to 0.94). There was no difference in breast cancer-specific mortality between atenolol users and matched nonusers (HR, 1.16; 95% CI, 0.84 to 1.61). Where differences in the distribution of covariates, such as medication use, existed between user and nonuser groups, we performed sensitivity analyses to determine the influence of these on the observed results. None of these had a notable effect on the results.
DISCUSSION
The results of this study suggest that the use of propranolol, a nonselective ␤ 1 /␤ 2 -adrenergic receptor antagonist, is associated with less advanced disease at diagnosis and lower breast cancer-specific mortality. Women taking propranolol in the year before breast cancer diagnosis were significantly less likely to present with a T4 tumor, node-positive (N2/N3), or metastatic disease when compared with those not taking a beta blocker. Furthermore, a longer duration of propranolol use was associated with fewer T4 tumors suggesting the possibility of a dose-response relationship. Propranolol use was also associated with low or intermediate tumor grade at diagnosis. The most notable result from this study was the finding that propranolol users had a significantly lower risk of breast cancer-specific mortality when compared with nonusers matched for age, comorbidity, tumor stage, and grade. There was no association observed between any of the study outcomes and use of the ␤ 1 selective antagonist atenolol. This is also consistent with data from preclinical studies [8] [9] [10] 13, 15, 17 and suggests that the effects of propranolol observed in this study are the result of ␤ 2 -adrenergic receptor antagonism.
Evidence from preclinical studies has demonstrated that ␤ 2 -adrenergic signaling plays a role in several pathways necessary for breast tumor progression and metastasis. These include the promotion of tumor cell invasion and migration, [8] [9] [10] the regulation of immune responses to tumor cells, 16 the inhibition of apoptosis, 17, 18 and the induction of vascular endothelial growth factor expression. 13 It has been shown that these effects are mediated through several downstream signaling pathways. 5 Preclinical evidence has also shown that the upregulation of ␤-adrenergic signaling does not exert a significant effect on primary breast tumor growth. 16 This is supported by results from the analysis of T4 tumor incidence (Table 3) , which suggest that propranolol use is not associated with an overall reduction in tumor size. Studies comparing ␤ 1 and ␤ 2 receptor antagonists have demonstrated that the effects of ␤-adrenergic signaling on tumor progression and metastasis are inhibited by ␤ 2 antagonists but not ␤ 1 antagonists. 9, 17 Similar results have been observed in studies that used short interfering RNA to selectively inhibit the expression of ␤ 1 or ␤ 2 adrenergic receptors by tumor cells. 13, 17 Several factors predictive of in vitro or in vivo responses to the inhibition of ␤ 2 adrenergic signaling have been identified. These include the expression of ␤ 2 adrenergic receptors by breast tumor cells and the level of sympathetic nervous system activation. 16 Although the effects of ␤-adrenergic signaling and its inhibition on breast tumor progression and metastasis have been well established in preclinical models, little clinical data exist to confirm these observations. Several observational studies of beta blocker use and breast cancer have been published. [37] [38] [39] [40] However, most of these studies have focused on the association between beta blocker use and cancer incidence. They have also studied beta blockers as a single homogenous pharmacologic group, without accounting for differences in ␤ 1 and ␤ 2 receptor activity. None of these studies have demonstrated an association between beta blocker use and breast tumor incidence. [38] [39] [40] This is consistent with evidence from epidemiologic and preclinical studies, which have shown little association between the upregulation of adrenergic signaling and tumorigenesis.
2 In a recently published observational study, it was shown that the use of beta blockers by hypertensive women with breast cancer was associated with a significant reduction in the formation of distant metastases and a 71% reduced risk of breast cancer-related mortality. 37 However, no distinction was made in this study between the use of beta blockers with selective ␤ 1 (n ϭ 32) or ␤ 2 (n ϭ 11) receptor activity. Two studies examining the perioperative use of propranolol in patients with breast 41 and colon 42 cancer are ongoing and their findings, if promising, will provide support for further investigation of agents targeting ␤-adrenergic signaling pathways.
This study has several strengths. It is the first, to the best of our knowledge, to examine the association between the use of beta blockers with varying ␤ 1 /␤ 2 -adrenergic receptor activity and breast cancerspecific mortality. It is based on prospectively collected data from a large nationally representative linked cancer and prescribing database. Detailed information on patient demographics, patient outcomes, tumor characteristics and, importantly, the dose, duration, and timing of beta blocker exposure was available from this database. There were also several limitations to this study. The inclusion of prevalent propranolol users, in addition to new initiators, may have introduced confounding due to healthy adherer effects. 34 However, the effects of this are likely to have been reduced by matching based on propensity scores that reflect participation in healthy behaviors. These inclusion criteria were also used to define atenolol users for whom no association between exposure and outcome was observed. Propranolol and atenolol are primarily prescribed for similar cardiovascular indications, such as hypertension, although because of its broader receptor activity and ability to cross the blood-brain barrier, propranolol is also indicated for the control of tremor, migraine prophylaxis, and treatment of cluster or tension headache. These additional indications are minor and are unlikely to have been associated with substantial confounding. Finally, although a large source population (n ϭ 5,801) was available for this study, the size of the propranolol user group limits the ability to fully explore dose-response relationships and the effects of propranolol exposure on subgroups of patients. We cannot exclude the possibility that the results were due to chance. Further studies in larger cohorts are required to confirm our findings.
In conclusion, the results presented here provide evidence in humans that confirm in vivo and in vitro observations that antagonism of the ␤ 2 -adrenergic receptor alters its signaling and subsequent tumor-related sequelae in a favorable manner. These results support the role of ␤-adrenergic signaling pathways in the regulation of breast tumor progression and suggest that interventions targeting these pathways may complement existing breast cancer therapies.
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